Dermavant Sciences Ltd. has a market-cap of $319 million.
Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.
Dermavant Sciences Ltd. provided the following description of their company for its IPO: ” We are a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. We have a robust medical dermatology pipeline with both late-stage and early-development product candidates. Our pipeline targets specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. “.
Dermavant Sciences Ltd. was founded in 2015 and has 0 employees. The company is located at Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom and can be reached via phone at +44 (117) 918-1293 or on the web at http://www.dermavant.com.
Receive News & Ratings for Dermavant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermavant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.